Human Embryonic Stem Cell (hESC) Products Industry - Opportunities and Forecasts to 2017

DUBLIN, Ireland, January 28, 2014 /PRNewswire/ --

Research and Markets (http://www.researchandmarkets.com/research/kdgxkz/opportunities_in) has announced the addition of the "Human Embryonic Stem Cell (hESC) Products Industry - Opportunities and Forecasts to 2017" report to their offering. 

     (Logo: http://photos.prnewswire.com/prnh/20130307/600769 )

Stem cells are primitive cells found in all multi-cellular organisms that are characterized by self-renewal and the capacity to differentiate into any mature cell type. Categorized by stage of life, several broad categories of stem cells exist, including:

• Embryonic stem cells, derived from blastocysts
• Post-natal stem cells, derived from newborn tissues
• Adult stem cells, found in adult tissues - including hematopoietic stem cells, mesenchymal stem cells, neural stem cells, and more
• Induced pluripotent stem cells, reprogrammed from adult cells
• Cancer stem cells, which give rise to clonal populations of cells that form tumors or disperse in the body

Embryonic stem cells are stem cells derived from the inner cell mass of a blastocyst, which is a stage reached four to five days post-fertilization. They are the most pluripotent of all stem cell types and can develop into over 200 different cell types of the human body. Human embryonic stem cells (hESCs) were first derived from mouse embryos in 1981 by Martin Evans and Matthew Kaufman, and independently by Gail R. Martin. 


Key Topics Covered: 

I. STRATEGIC OVERVIEW

II. ACCESS & AVAILABILITY OF hESC LINES
A. NIH Registry Approved hESC Lines
B. Sources of Additional Published hESC Lines
C. Sources of Additional Unpublished hESC Lines

III. END-USER APPLICATIONS OF hESCs
A. Basic Research
B. Cellular Therapies
C. Tissue Engineering
D. Toxicology Testing

IV. PATENT ENVIRONMENT
A. Landmark hESC Patents: WARF Composition of Matter Patents
B. Global Stem Cell Patent Landscape
C. U.S. Patents of Importance
D. Worldwide Patents of Importance
E. Summary of the hESC Intellectual Property Landscape

V. MARKET TREND ANALYSIS - FUTURE GROWTH PROJECTIONS
A. Scientific Publication Analysis
B. Grant Analysis
C. Patent Analysis

VI. MARKET SIZE
A. Definitions
B. Experimental Approach
C. Annual Market Size - Human Embryonic Stem Cell Products

VII. MARKET CHARACTERIZATION
A. Key Research Applications
B. Geographical Breakdown (Country-by-Country Breakdown)

VIII. hESC RESEARCH SUPPLY COMPETITORS
A. Cellartis AB
B. Vitrolife
C. Tataa Biocenter
D. Invitrogen
E. Stem Cell Technologies
F. BD Biosciences
G. Chemicon
H. R&D Systems
I. SA Biosciences
J. Thermo Scientific
K. Australian Stem Cell Centre

IX. SPECIALTY PHARMACEUTICAL COMPANIES DEVELOPING hESC THERAPIES
A. Geron
B. Novocell
C. Cell Cure Neurosciences Ltd
D. Cell Dynamics International
E. Advanced Cell Technology

X. TOXICOLOGY TESTING LEGISLATION
A. European Union Ban of Animal-Testing for Cosmetic Development (2013)
B. Responses to the European Ban on Animal Testing for Cosmetic Development
C. EU Legislation Regarding Animal-Based Testing for Drug Discovery

XI. STRATEGIC PRODUCT & TECHNOLOGY DEVELOPMENT
A. Product Categories
B. Product Ideas & Suggestions

XII. STRATEGIES FOR ACCESSING THE MARKETPLACE
A. Top Research Institutions Performing hESC Research
B. Events of Interest - hESC Conferences & Symposiums

XIII. SCIENTIST PANEL: DETAILED END-USER SURVEY
A. Survey Overview
B. Characterization of Market Survey Respondents
C. Survey Findings
D. Terms Used in Online Product Search

XIV. CONCLUSIONS

APPENDIX

Human Embryonic Stem Cell Research Centers & Contact Information 

Companies Mentioned:

• Australian Stem Cell Centre
• BD Biosciences
• Cellartis AB
• Chemicon
• Geron
• Invitrogen
• Novocell
• R&D Systems
• SA Biosciences
• Tataa Biocenter
• Thermo Scientific
• Vitrolife

For more information visit http://www.researchandmarkets.com/research/kdgxkz/opportunities_in

Media Contact: Laura Wood , +353-1-481-1716, press@researchandmarkets.net